ORIGINAL ARTICLE

JOP. J Pancreas (Online) 2004; 5(6):464-475.

Cholecystokinin Octapeptide: A Potential Growth Factor for Pancreatic Beta Cells in Diabetic Rats

Emmanuelle Kuntz, Michel Pinget, Christiane Damgé

European Center for Study of Diabetes, Faculty of Medicine, Strasbourg, France

ABSTRACT

Context Diabetes is associated with the reduction of beta cell mass and activity. Cholecystokinin (CCK) is known to induce growth of the exocrine pancreas and to stimulate insulin secretion.

Objective We investigated the possible role of CCK-octapeptide (CCK-8) in generating islet cell proliferation in type 1 and type 2 diabetic rats.

Methods Streptozotocin-induced type 1 diabetic rats, streptozotocin/nicotinamide-induced type 2 diabetic rats and non-diabetic rats were subjected to CCK-8 (1, 2 and 4 mg/kg) or saline injections (for the control group), three times daily for 8 successive days.

Main outcome measures The islets of Langerhans were analyzed morphometrically; the beta-cell function was evaluated by an oral glucose tolerance test, and plasma basal glucose and insulin concentrations.

Results In type 1 diabetic rats, CCK-8 induced an increase in beta cell surface associated with a marked increase in the mitotic index; this effect appeared at a concentration of 1 mg/kg CCK-8 and was the highest at a concentration of 4 mg/kg CCK-8. In addition, pancreatic- and plasma-insulin concentrations increased while fasting blood glucose concentrations were reduced when compared to saline-treated rats but the glycemic response to an oral glucose challenge did not significantly improve. In type 2 diabetic rats and in non-diabetic rats, CCK-8 treatment did not significantly affect either the structure or the functional state of beta-cells.

Conclusions CCK-8 could improve blood glucose concentrations in type 1 diabetic rats correlated with an increase in beta cell mass probably potentiated by the chronic hyperglycemic state.

Full text: HTML format   PDF format
  Look up who cited this article

References

  1. Bonner-Weir S, Baxter LA, Schuppin GT, Smith FE. A second pathway for regeneration of adult exocrine and endocrine pancreas. A possible recapitulation of embryonic development. Diabetes 1993; 42:1715-20. [More details]

  2. Parsons JA, Brelje TC, Sorenson RL. Adaptation of islets of Langerhans to pregnancy: increased islet cell proliferation and insulin secretion correlates with the onset of placental lactogen secretion. Endocrinology 1992; 130:1459-66. [More details]

  3. Yonemura Y, Takashima T, Miwa K, Miyazaki I, Yamamoto H, Okamoto H. Amelioration of diabetes mellitus in partially depancreatized rats by poly(ADP-ribose) synthetase inhibitors. Evidence of islet B-cell regeneration. Diabetes 1984; 33:401-4. [More details]

  4. Logsdon CD. Stimulation of pancreatic acinar cell growth by CCK, epidermal growth factor, and insulin in vitro. Am J Physiol 1986; 251:G487-94. [More details]

  5. Axelson J, Hakanson R, Ihse I, Lilja I, Rehfeld JF, Sundler F. Effects of endogenous and exogenous cholecystokinin and of infusion with the cholecystokinin antagonist L-364,718 on pancreatic and gastrointestinal growth. Scand J Gastroenterol 1990; 25:471-80. [More details]

  6. Damgé C, Hajri A, Lhoste E, Aprahamian M. Comparative effect of chronic bombesin, gastrin-releasing peptide and caerulein on the rat pancreas. Regul Pept 1988; 20:141-50. [More details]

  7. Hajri A, Damgé C. Effects of cholecystokinin octapeptide on pancreatic acinar carcinoma in the rat. Pharm Res 1998; 15:1767-74. [More details]

  8. Hajri A, Aprahamian M, Damgé C. Effect of a new CCK-receptor antagonist, CR 1409, on pancreatic growth induced by caerulein, CCK-8, bombesin and gastrin-releasing peptide in the rat. Digestion 1989; 43:66-72. [More details]

  9. Povoski SP, Zhou W, Longnecker DS, Jensen RT, Mantey SA, Bell RH Jr. Stimulation of in vivo pancreatic growth in the rat is mediated specifically by the way of cholecystokinin-A receptors. Gastroenterology 1994; 107:1135-46. [More details]

  10. Shimizu K, Kato Y, Shiratori K, Ding Y, Song Y, Furlanetto R, et al. Evidence for the existence of CCK-producing cells in rat pancreatic islets. Endocrinology 1998; 139:389-96. [More details]

  11. Morisset J, Julien S, Lainé J. Localization of cholecystokinin receptor subtypes in the endocine pancreas. J Histochem Cytochem 2003; 51:1501-13. [More details]

  12. Tachibana I, Akiyama T, Kanagawa K, Shiohara H, Furumi K, Watanabe N, Otsuki. M. Defect in pancreatic exocrine and endocrine response to CCK in genetically diabetic OLETF rats. Am J Physiol 1996; 270:730-7. [More details]

  13. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41:1422-8. [More details]

  14. Stern JS, Johnson PR, Batchelor BR, Zucker LM, Hirsch J. Pancreatic insulin release and peripheral tissue resistance in Zucker obese rats fed high- and low-carbohydrate diets. Am J Physiol 1975; 228:543-8. [More details]

  15. Zucker LM. Hereditary obesity in the rat associated with hyperlipemia. Ann N Y Acad Sci 1965; 131:447-58. [More details]

  16. Kim KH, Lee HS, Kim CD, Chun HJ, Song CW, Um SH, et al. Evaluation of pancreatic exocrine function using pure pancreatic juice in non insulin-dependent diabetes mellitus. J Clin Gastroenterol 2000; 31:51-4. [More details]

  17. Ahren B, Pettersson M, Uvnas-Moberg K, Gutniak M, Efendic S. Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide on basal and meal-stimulated pancreatic hormone secretion in man. Diabetes Res Clin Pract 1991; 13:153-162. [More details]

  18. Takacs T, Hegyi P, Jarmay K, Czako L, Gog C, Rakonczay Z Jr, et al. Cholecystokinin fails to promote pancreatic regeneration in diabetic rats following the induction of experimental pancreatitis. Pharmacol Res 2001; 44:363-72. [More details]

  19. Zawalich WS, Diaz VA, Zawalich KC. Stimulatory effects of cholecystokinin on isolated perifused islets inhibited by potent and specific antagonist L 364718. Diabetes 1988; 37:1432-7. [More details]

  20. Mineo H, Iwaki N, Kogishi K, Zabielski R, Onaga T, Kato S. Effects of intravenous infusions of cholecystokinin (CCK)-8 on exocrine and endocrine pancreatic secretion in conscious sheep. Comp Biochem Physiol A Physiol 1995; 111:133-8. [More details]

  21. Ahren B, Holst JJ, Efendic S. Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J Clin Endocrinol Metab 2000; 85:1043-8. [More details]

  22. Reimers J, Nauck M, Creutzfeldt W, Strietzel J, Ebert R, Cantor P, Hoffmann G. Lack of insulinotropic effect of endogenous and exogenous cholecystokinin in man. Diabetologia 1988; 31:271-80. [More details]

  23. Masiello P, Broca C, Gross R, Roye M, Manteghetti M; Hillaire-Buys D, et al. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 1998; 47:224-9. [More details]

  24. Novelli M, Fabregat ME, Fernandez-Alvarez J, Gomis R, Masiello P. Metabolic and functional studies on isolated islets in a new rat model of type 2 diabetes. Mol Cell Endocrinol 2001; 175:57-66. [More details]

  25. Kuntz E, Pinget M, Damgé C. Effects of cholecystokinin octapeptide on the exocrine pancreas in a new rat model of type 2 diabetes. Eur J Pharmacol 2002; 448:253-61. [More details]

  26. Wang RN, Kloppel G, Bouwens L. Duct- to islet-cell differentiation and islet growth in the pancreas of duct-ligated adult rats. Diabetologia 1995; 38:1405-11. [More details]

  27. Rosenberg L, Brown RA, Duguid WP. A new approach to the induction of duct epithelial hyperplasia and nesidioblastosis by cellophane wrapping of the hamster pancreas. J Surg Res 1983; 35:63-72. [More details]

  28. Rosenberg L, Duguid WP, Vinik AI. The effect of cellophane wrapping of the pancreas in the Syrian golden hamster: autoradiographic observations. Pancreas 1989; 4:31-7. [More details]

  29. Hardikar AA. Generating new pancreas from old. Trends Endocrinol Metab 2004; 15:198-203. [More details]

  30. Rushakoff RJ, Goldfine ID, Carter JD, Liddle RA. Physiological concentrations of cholecystokinin stimulate amino acid- induced insulin release in humans. J Clin Endocrinol Metab 1987; 65:395-401. [More details]

  31. Schmid R, Schusdziarra V, Schulte-Frohlinde E, Maier V, Classen M. Effect of CCK on insulin, glucagon, and pancreatic polypeptide levels in humans. Pancreas 1989; 4:653-61. [More details]

  32. Zawalich W, Takuwa N, Takuwa Y, Diaz VA, Rasmussen H. Interactions of cholecystokinin and glucose in rat pancreatic islets. Diabetes 1987; 36:426-33. [More details]

  33. Hardikar AA, Wang XY, Williams LJ, Kwok J, Wong R, Yao M, Tuch BE. Functional maturation of fetal porcine beta-cells by glucagon-like peptide 1 and cholecystokinin. Endocrinology 2002; 143:3505-14. [More details]

  34. Swenne I. The role of glucose in the in vitro regulation of cell cycle kinetics and proliferation of fetal pancreatic B-cells. Diabetes 1982; 31:754-60. [More details]

Keywords Cholecystokinin; Diabetes Mellitus, Type I; Diabetes Mellitus, Type II; Islets of Langerhans

Correspondence Christiane Damgé; christiane.damge@medecine.u-strasbg.fr